Payment overview · 2025
General Payments
$77.57
3 reported records · 3 companies
Healthcare provider profile · identity verified
Joseph P. Mathew, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · RACINE, WI · NPI 1023031853
Verified facts
What the public records show
CMS Open Payments records show Joseph P. Mathew, M.D. received $77.57 in general payments during 2025 across 3 reported records.
Dynavax Technologies Corporation accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $31.42 | 40.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.62 | 31.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.53 | 27.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $77.57 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 922 | 240 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 516 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 475 | 135 |
| Lisinopril | Lisinopril | 467 | 134 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 423 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 71 |
| Omeprazole | Omeprazole | 251 | 57 |
| Alendronate Sodium | Alendronate Sodium | 213 | 50 |
| Sertraline Hcl | Sertraline Hcl | 208 | 44 |
| Furosemide | Furosemide | 173 | 55 |
| Potassium Chloride | Potassium Chloride | 172 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 44 |
| Losartan Potassium | Losartan Potassium | 164 | 49 |
| Metformin Hcl | Metformin Hcl | 161 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 44 |
| Gabapentin | Gabapentin | 138 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 137 | 28 |
| Metformin Hcl Er | Metformin Hcl | 133 | 42 |
| Ezetimibe | Ezetimibe | 132 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 32 |
| Simvastatin | Simvastatin | 122 | 31 |
| Glimepiride | Glimepiride | 108 | 31 |
| Warfarin Sodium | Warfarin Sodium | 106 | 17 |
| Allopurinol | Allopurinol | 102 | 26 |
| Eliquis | Apixaban | 93 | 16 |
| Montelukast Sodium | Montelukast Sodium | 90 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 22 |
| Prednisone | Prednisone | 82 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 23 |
| Donepezil Hcl | Donepezil Hcl | 80 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 21 |
| Alprazolam | Alprazolam | 72 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 33 |
| Bupropion Xl | Bupropion Hcl | 60 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 23 |
| Carvedilol | Carvedilol | 54 | 20 |
| Spironolactone | Spironolactone | 54 | 16 |
| Trazodone Hcl | Trazodone Hcl | 50 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 47 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 16 |
| Famotidine | Famotidine | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | 12 |
| Naproxen | Naproxen | 44 | 16 |
| Tramadol Hcl | Tramadol Hcl | 44 | 18 |
| Atenolol | Atenolol | 43 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 15 |
| Mirtazapine | Mirtazapine | 41 | suppressed |
| Meloxicam | Meloxicam | 40 | 14 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | 16 |
| Finasteride | Finasteride | 32 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | 14 |
| Ozempic | Semaglutide | 32 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 23 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Cholestyramine Light | Cholestyramine | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Striverdi Respimat | Olodaterol Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77.57 · 3 records | Dynavax Technologies Corporation | Cologuard Collection Kit, Heplisav-B | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error